Identification of host–pathogen-disease relationships using a scalable multiplex serology platform in UK Biobank

[1]  T. Yates,et al.  Human Cytomegalovirus and Risk of Incident Cardiovascular Disease in UK Biobank , 2021, The Journal of infectious diseases.

[2]  J. Knight,et al.  Host genetics and infectious disease: new tools, insights and translational opportunities , 2020, Nature Reviews Genetics.

[3]  N. Allen,et al.  Characterization of human papillomavirus (HPV) 16 E6 seropositive individuals without HPV-associated malignancies after 10 years of follow-up in the UK Biobank , 2020, EBioMedicine.

[4]  T. Olsson,et al.  Epstein–Barr virus infection after adolescence and human herpesvirus 6A as risk factors for multiple sclerosis , 2020, European journal of neurology.

[5]  G. Duan,et al.  A meta‐analysis of the association between Helicobacter pylori infection and risk of atherosclerotic cardiovascular disease , 2020, Helicobacter.

[6]  R. Baiocchi,et al.  Immunology of EBV-Related Lymphoproliferative Disease in HIV-Positive Individuals , 2020, Frontiers in Oncology.

[7]  C. Diaconu,et al.  The impact of infection with hepatitis C virus on cardiovascular risk. , 2020, American journal of cardiovascular disease.

[8]  G. Stewart,et al.  The interaction of Multiple Sclerosis risk loci with Epstein-Barr virus phenotypes implicates the virus in pathogenesis , 2020, Scientific Reports.

[9]  A. Tjønneland,et al.  Timing of HPV16-E6 antibody seroconversion before OPSCC: findings from the HPVC3 consortium , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  D. Westreich,et al.  UK Biobank, big data, and the consequences of non-representativeness , 2019, The Lancet.

[11]  M. Pawlita,et al.  Development and validation of HIV-1 Multiplex Serology. , 2019, Journal of immunological methods.

[12]  P. Hartge,et al.  Antibodies Against Chlamydia trachomatis and Ovarian Cancer Risk in Two Independent Populations , 2019, Journal of the National Cancer Institute.

[13]  P. Klenerman,et al.  Validation of Multiplex Serology for human hepatitis viruses B and C, human T-lymphotropic virus 1 and Toxoplasma gondii , 2019, PloS one.

[14]  F. Grodstein,et al.  Serologic Response to Helicobacter pylori Proteins Associated With Risk of Colorectal Cancer Among Diverse Populations in the United States. , 2019, Gastroenterology.

[15]  A. Mentzer,et al.  Validation of Multiplex Serology detecting human herpesviruses 1-5 , 2018, PloS one.

[16]  M. Snijder,et al.  Differences in Chlamydia trachomatis seroprevalence between ethnic groups cannot be fully explained by socioeconomic status, sexual healthcare seeking behavior or sexual risk behavior: a cross-sectional analysis in the HEalthy LIfe in an Urban Setting (HELIUS) study , 2018, BMC Infectious Diseases.

[17]  L. Margolis,et al.  Cytomegalovirus Infection in Cardiovascular Diseases , 2018, Biochemistry (Moscow).

[18]  P. Donnelly,et al.  The UK Biobank resource with deep phenotyping and genomic data , 2018, Nature.

[19]  H. Forbes,et al.  Viral load and antibody boosting following herpes zoster diagnosis , 2018, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[20]  P. Stern,et al.  Opportunities and challenges for human papillomavirus vaccination in cancer , 2018, Nature Reviews Cancer.

[21]  S. Ng,et al.  Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. , 2017, Gastroenterology.

[22]  Cathie Sudlow,et al.  UK Biobank: opportunities for cardiovascular research , 2017, European heart journal.

[23]  K. Davison,et al.  Human T-lymphotropic viruses (HTLV) in England and Wales, 2004 to 2013: testing and diagnoses , 2017, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[24]  Anne M Johnson,et al.  Chlamydia trachomatis Pgp3 Antibody Population Seroprevalence before and during an Era of Widespread Opportunistic Chlamydia Screening in England (1994-2012) , 2017, PloS one.

[25]  Mirjam Kretzschmar,et al.  Infectious reactivation of cytomegalovirus explaining age- and sex-specific patterns of seroprevalence , 2017, bioRxiv.

[26]  D. Mabey,et al.  Defining Seropositivity Thresholds for Use in Trachoma Elimination Studies , 2017, PLoS neglected tropical diseases.

[27]  A. Petruzziello,et al.  Hepatitis C virus (HCV) genotypes distribution: an epidemiological up-date in Europe , 2016, Infectious Agents and Cancer.

[28]  L. Young,et al.  Epstein–Barr virus: more than 50 years old and still providing surprises , 2016, Nature Reviews Cancer.

[29]  D. Hill,et al.  The prevalence and genotypic analysis of Toxoplasma gondii from individuals in Scotland, 2006–2012 , 2016, Parasites & Vectors.

[30]  C Jessica E Metcalf,et al.  Use of serological surveys to generate key insights into the changing global landscape of infectious disease , 2016, The Lancet.

[31]  B. Christensen,et al.  Prospective Study of Human Polyomaviruses and Risk of Cutaneous Squamous Cell Carcinoma in the United States , 2016, Cancer Epidemiology, Biomarkers & Prevention.

[32]  J. Blangero,et al.  Genetic loci for Epstein-Barr virus nuclear antigen-1 are associated with risk of multiple sclerosis , 2016, Multiple sclerosis.

[33]  M. Lederman,et al.  Partners in Crime: The Role of CMV in Immune Dysregulation and Clinical Outcome During HIV Infection , 2016, Current HIV/AIDS Reports.

[34]  David Moher,et al.  STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies , 2015, BMJ : British Medical Journal.

[35]  K. Looker,et al.  Global and Regional Estimates of Prevalent and Incident Herpes Simplex Virus Type 1 Infections in 2012 , 2015, PloS one.

[36]  J. Fellay,et al.  Amino Acid Variation in HLA Class II Proteins Is a Major Determinant of Humoral Response to Common Viruses , 2015, American journal of human genetics.

[37]  Calliope A. Dendrou,et al.  Class II HLA interactions modulate genetic risk for multiple sclerosis , 2015, Nature Genetics.

[38]  M. Cortina-Borja,et al.  Hepatitis C virus seroprevalence in pregnant women delivering live-born infants in North Thames, England in 2012 , 2015, Epidemiology and Infection.

[39]  S. Franceschi,et al.  Hepatitis C Virus Seroprevalence in Mongolian Women Assessed by a Novel Multiplex Antibody Detection Assay , 2015, Cancer Epidemiology, Biomarkers & Prevention.

[40]  P. Elliott,et al.  UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age , 2015, PLoS medicine.

[41]  W. Ahrens,et al.  Human Papillomavirus 16 E6 Antibodies in Individuals without Diagnosed Cancer: A Pooled Analysis , 2015, Cancer Epidemiology, Biomarkers & Prevention.

[42]  H. Agut,et al.  Classification of HHV-6A and HHV-6B as distinct viruses , 2014, Archives of Virology.

[43]  A. Zhang,et al.  Anti‐JC virus (JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial , 2014, European journal of neurology.

[44]  John Wright,et al.  Seroprevalence of Cytomegalovirus, Epstein Barr Virus and Varicella Zoster Virus among Pregnant Women in Bradford: A Cohort Study , 2013, PloS one.

[45]  J. Dowd,et al.  Seroprevalence of Epstein-Barr Virus Infection in U.S. Children Ages 6-19, 2003-2010 , 2013, PloS one.

[46]  M. Salminen,et al.  Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening , 2013, BMC Infectious Diseases.

[47]  A. Avenell,et al.  Systematic Review and Meta-Analysis of the Sero-Epidemiological Association between Epstein Barr Virus and Multiple Sclerosis , 2013, PloS one.

[48]  A. Gavin,et al.  Prevalence of human papillomavirus in women attending cervical screening in the UK and Ireland: New data from northern Ireland and a systematic review and meta‐analysis , 2013, Journal of medical virology.

[49]  S. Sharp,et al.  Higher immunoglobulin G antibody levels against cytomegalovirus are associated with incident ischemic heart disease in the population-based EPIC-Norfolk cohort. , 2012, The Journal of infectious diseases.

[50]  H. D. de Melker,et al.  Changes in Antibody Seroprevalence of Seven High-Risk HPV Types between Nationwide Surveillance Studies from 1995–96 and 2006–07 in The Netherlands , 2012, PloS one.

[51]  A. Gessain,et al.  Epidemiological Aspects and World Distribution of HTLV-1 Infection , 2012, Front. Microbio..

[52]  E. Barbosa-Stancioli,et al.  Human T-Lymphotropic Viruses (HTLV) , 2012 .

[53]  Gretchen A. Stevens,et al.  Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. , 2012, Vaccine.

[54]  V. Sondak,et al.  Case–control Study of Merkel Cell Polyomavirus Infection and Cutaneous Squamous Cell Carcinoma , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[55]  J. Parry,et al.  Prevalence of markers for HIV, hepatitis B and hepatitis C infection in UK military recruits , 2011, Epidemiology and Infection.

[56]  M. Cannon,et al.  Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection , 2010, Reviews in medical virology.

[57]  M. Pawlita,et al.  Prevalence and stability of antibodies to the BK and JC polyomaviruses: a long-term longitudinal study of Australians. , 2010, The Journal of general virology.

[58]  M. Cannon,et al.  Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988-2004. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[59]  M. Pawlita,et al.  Helicobacter pylori Multiplex Serology , 2009, Helicobacter.

[60]  D. Galloway,et al.  Association of Merkel Cell Polyomavirus–Specific Antibodies With Merkel Cell Carcinoma , 2009, Journal of the National Cancer Institute.

[61]  K. Straif,et al.  A review of human carcinogens--Part B: biological agents. , 2009, The Lancet. Oncology.

[62]  A. Presanis,et al.  Situation of HIV infections and STIs in the United Kingdom in 2007. , 2008, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[63]  M. Pawlita,et al.  Seroprevalence of 34 Human Papillomavirus Types in the German General Population , 2008, PLoS pathogens.

[64]  E. L. Miller,et al.  The comparative sero-epidemiology of varicella zoster virus in 11 countries in the European region. , 2007, Vaccine.

[65]  J. Lünemann,et al.  Epstein-Barr virus and multiple sclerosis , 2007 .

[66]  G. Cutter,et al.  Infectious causes of multiple sclerosis , 2006, The Lancet Neurology.

[67]  M. Pawlita,et al.  Suppression of non-specific binding in serological Luminex assays. , 2006, Journal of immunological methods.

[68]  Markus F Templin,et al.  Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. , 2005, Clinical chemistry.

[69]  K. Ward.  The natural history and laboratory diagnosis of human herpesviruses-6 and -7 infections in the immunocompetent. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[70]  H. D. de Melker,et al.  The seroepidemiology of herpes simplex virus type 1 and 2 in Europe , 2004, Sexually Transmitted Infections.

[71]  Jennifer S. Smith,et al.  Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. , 2002, The Journal of infectious diseases.

[72]  W. Edmunds,et al.  Sero‐epidemiological patterns of epstein‐barr and herpes simplex (HSV‐1 and HSV‐2) viruses in England and Wales , 2002, Journal of medical virology.

[73]  F. Goebel,et al.  Kaposi's sarcoma‐associated herpesvirus serology in Europe and Uuganda: Multicentre study with multiple and novel assays , 2001, Journal of medical virology.

[74]  M. Pawlita,et al.  A generic capture ELISA for recombinant proteins fused to glutathione S-transferase: validation for HPV serology. , 2001, Journal of immunological methods.

[75]  K. Mühlemann,et al.  Age-specific seroprevalence to varicella-zoster virus: study in Swiss children and analysis of European data. , 2001, Vaccine.

[76]  B. Horne,et al.  Prospective Study of Pathogen Burden and Risk of Myocardial Infarction or Death , 2001, Circulation.

[77]  P. Simmonds,et al.  Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen , 1996, The Lancet.

[78]  Z. Berneman,et al.  Human herpesvirus-7 (HHV-7): current status. , 1995, Clinical and diagnostic virology.

[79]  M. H. Jackson,et al.  A seroepidemiological survey of toxoplasmosis in Scotland and England. , 1987, Annals of tropical medicine and parasitology.

[80]  T. Olsson,et al.  Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis , 2017, Nature Reviews Neurology.

[81]  D. Schadendorf,et al.  Merkel cell carcinoma: Epidemiology, prognosis, therapy and unmet medical needs. , 2017, European journal of cancer.

[82]  M. Zwahlen,et al.  HIV and human herpesvirus 8 co‐infection across the globe: Systematic review and meta‐analysis , 2016, International journal of cancer.

[83]  Bernard Roizman,et al.  Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis , 2007 .

[84]  Georges Daube,et al.  Euro Surveillance : Bulletin Européen sur les Maladies Transmissibles , 2005 .

[85]  Cather Jc,et al.  Herpes simplex virus type 1 infections. , 1998 .

[86]  E. Somers.  International Agency for Research on Cancer. , 1985, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.